Three Months 2026 Financial and Business Highlights
- Total three months revenues of
$2.9 million – an increase of approximately 15% - Healthcare revenues of
$2.8 million in Q1 2026 – an increase of approximately 19% - Net loss from operations of
$103,000 – a decrease of approximately 63% Net Cash of$5.5 million – a decrease of approximately 4%
Management Commentary
“In our first quarter of 2026 we saw a 15% year over year uptick in our total revenue, much of this growth came from our existing client base,” commented
"Building on our momentum in the first quarter, we are having a year of exciting innovation and expansion, in Human-Led, AI-Powered solutions and opening up an important healthcare segment” said
Financial Review for the Three Months Ended
Total revenues for the three months ended
The company reported a net loss for the three months of approximately
The company finished the quarter with approximately
Detailed financial information may be downloaded at www.liveworld.com/ir or at https://www.otcmarkets.com/stock/LVWD/overview.
About
Purpose-built for highly regulated healthcare and pharma brands,
“Safe Harbor" Statement Under The Private Securities Litigation Reform Act
This press release may contain forward-looking information concerning
LiveWorld Contacts
IR Contact:
dhouston@liveworld.com
(408) 615-8496
PR Contact:
mhammer@liveworld.com
(737) 212-9739
| UNAUDITED CONDENSED BALANCE SHEETS | |||||||
| (In thousands, except share data) | |||||||
| 2026 | 2025 | ||||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalent | $ | 6,796 | $ | 7,313 | |||
| Accounts receivable, net | 2,809 | 1,309 | |||||
| Prepaid expenses | 423 | 246 | |||||
| Total current assets | 10,028 | 8,868 | |||||
| Property and equipment, net | 22 | 18 | |||||
| Other assets | 27 | 27 | |||||
| Total assets | $ | 10,077 | $ | 8,913 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 468 | $ | 242 | |||
| Accrued employee expenses | 738 | 595 | |||||
| Other accrued liabilities | 1,295 | 1,555 | |||||
| Deferred revenue | 1,849 | 761 | |||||
| Total current liabilities | 4,350 | 3,153 | |||||
| Total liabilities | 4,350 | 3,153 | |||||
| Stockholders' equity | |||||||
| Common stock: 45,633,442 issued and outstanding as of | 34 | 34 | |||||
| Additional paid-in capital | 144,843 | 144,773 | |||||
| Accumulated deficit | (139,150 | ) | (139,047 | ) | |||
| Total stockholders' equity | 5,727 | 5,760 | |||||
| Total liabilities and stockholders' equity | $ | 10,077 | $ | 8,913 | |||
| CONDENSED STATEMENT OF OPERATIONS | |||||||
| (In thousands, except per share data) | |||||||
| Three Months Ended | |||||||
| 2026 | 2025 | ||||||
| Total revenues | $ | 2,949 | $ | 2,575 | |||
| Cost of revenues | 1,407 | 1,514 | |||||
| Gross Margin | 1,542 | 1,061 | |||||
| Operating Expense | |||||||
| Product development | 428 | 275 | |||||
| Sales and marketing | 416 | 440 | |||||
| General and administrative | 814 | 638 | |||||
| Total operating expense | 1,658 | 1,353 | |||||
| Income from operations | (116 | ) | (292 | ) | |||
| Income before tax | (116 | ) | (292 | ) | |||
| Other Income | 16 | 17 | |||||
| Provision for income taxes | 3 | (1 | ) | ||||
| Net income from operations | (103 | ) | (276 | ) | |||
| Earnings per share analysis from operations: | |||||||
| Basic income per share | $ | (0.00 | ) | $ | (0.01 | ) | |
| Shares used in computing basic loss per share | 45,633,442 | 45,633,442 | |||||
| Diluted net income (loss) per share | $ | (0.00 | ) | $ | (0.01 | ) | |
| Shares used in computing diluted income (loss) per share | 45,633,442 | 45,633,442 | |||||
| Departmental allocation of stock-based compensation: | |||||||
| Cost of revenues | $ | 16 | $ | 20 | |||
| Product development | 6 | 5 | |||||
| Sales and marketing | 5 | 8 | |||||
| General and administrative | 43 | 46 | |||||
| Total stock-based compensation | $ | 70 | $ | 79 | |||
| CONDENSED STATEMENTS OF CASH FLOWS | |||||||
| (In thousands) | |||||||
| Three Months Ended | |||||||
| 2026 | 2025 | ||||||
| Cash flows from operating activities: | |||||||
| Net income (loss) | $ | (103 | ) | $ | (276 | ) | |
| Adjustments to reconcile net income (loss) provided by (used in) operating activities: | |||||||
| Depreciation of long-lived assets | 4 | 6 | |||||
| Stock-based compensation | 70 | 79 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (1,500 | ) | (1,660 | ) | |||
| Other assets | (175 | ) | (171 | ) | |||
| Accounts payable | 226 | 31 | |||||
| Accrued liabilities | (118 | ) | (563 | ) | |||
| Deferred revenue | 1,088 | 1,000 | |||||
| Net cash provided by (used in) operating activities | (508 | ) | (1,554 | ) | |||
| Cash flows from investing activities: | |||||||
| Purchase of property and equipment | (9 | ) | (4 | ) | |||
| Net cash provided by (used in) investing activities | (9 | ) | (4 | ) | |||
| Cash flows from financing activities: | |||||||
| Proceeds from exercise of stock options | ------ | ----- | |||||
| Net cash provided by (used for) financing activities | ------ | ----- | |||||
| Change in cash and cash equivalent | (517 | ) | (1,558 | ) | |||
| Cash and cash equivalents, beginning of period | 7,313 | 6,603 | |||||
| Cash and cash equivalents, end of period | $ | 6,796 | $ | 5,045 | |||
| Supplemental disclosure of non-cash financing and investing activities: | |||||||
| Income tax paid | $ | 3 | $ | 1 | |||
Source: 